Search
(S)-camphor
go.drugbank.com/drugs/DB11345Approved(S)-camphor is not the naturally-occurring stereoisomer but displays similar TRPV channel affinity and current inhibition [A33086]. … [DB01744] is isolated from the wood of the camphor laurel tree, _Cinnamomum camphora_, and had a long history of medicinal use.
Droperidol
go.drugbank.com/drugs/DB00450ApprovedInvestigationalVet approved(From Martindale, The Extra Pharmacopoeia, 29th ed, p593) … It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the
Lumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigational[A20343] Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute … [A18395] The next most common mutation, G551D, affecting 4-5% of CF patients worldwide, is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening
Voriconazole
go.drugbank.com/drugs/DB00582ApprovedInvestigational[A236050] Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002.[L34660]
Ziprasidone
go.drugbank.com/drugs/DB00246ApprovedInvestigationalatypical antipsychotics) include [clozapine], [quetiapine], [olanzapine], [aripiprazole] and [ziprasidone] among others, and are generally thought to be as efficacious as first generation antipsychotics but … [A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.
Cyproheptadine
go.drugbank.com/drugs/DB00434ApprovedInvestigationalCyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in ...
Glecaprevir
go.drugbank.com/drugs/DB13879ApprovedInvestigationalMavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940]. … The ultimate goal of the combination treatment is to achieve sustained virologic response (SVR) and cure the patients from the infection.
Butamben
go.drugbank.com/drugs/DB11148ApprovedWithdrawnButamben is a local anesthetic in the form of n-butyl-p-aminobenzoate. … The FDA removed all parenteral butamben products from the market, possibly due to the poor solubility of this drug.[A254247,L43942]
Baloxavir marboxil
go.drugbank.com/drugs/DB13997ApprovedInvestigational[L4779] It was also approved by the European Commission on January 7, 2021.[L45241] … [A251760] Baloxavir marboxil was first globally approved in Japan in February 2018,[A39895] followed by the US approval in October, 2018.
Damoctocog alfa pegol
go.drugbank.com/drugs/DB14700ApprovedInvestigationalIn order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized. … [L4576,A38909] This product has been engineered by Bayer[L4576] and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018.[F1609]